Limits...
Hereditary breast and ovarian cancer.

Gronwald J, Byrski T, Huzarski T, Oszurek O, Janicka A, Szymanska-Pasternak J, Górski B, Menkiszak J, Rzepka-Górska I, Lubinski J - Hered Cancer Clin Pract (2008)

View Article: PubMed Central - HTML - PubMed

Affiliation: International Hereditary Cancer Centre, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. jgron@sci.pam.szczecin.pl

ABSTRACT

Around 14 000 women develop breast or ovarian cancer in Poland every year. Advances in clinical genetics of cancers allow a significant number of these cancers to be prevented. Additionally, patients of known genetic background may be more effectively diagnosed and treated due to the application of special, nonstandard systems of control examinations and treatment.

No MeSH data available.


Family with HOC syndrome and diagnosed constitutional 4153delA BRCA1 gene mutation.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2735784&req=5

Figure 1: Family with HOC syndrome and diagnosed constitutional 4153delA BRCA1 gene mutation.

Mentions: Breast and ovarian cancer in BRCA1 carriers have particular clinical characteristics. The mean age at onset of breast cancer is about 42-45 years [15,16] and of ovarian cancer is about 54 years [17,18]. 18-32% of breast cancers are bilateral [19,20]. These are rapidly growing tumours: >90% of cases have G3 grade at the time of diagnosis and almost all ovarian cancers in women with a BRCA1 mutation are diagnosed in FIGO stage III°/IV°. Medullary, atypical medullary, ducal and oestrogen receptor negative (ER) breast tumours are common in BRCA1 carriers. BRCA1 mutation-positive tumours constitute about 10-15% of all ER-breast cancers [21-23]. Most carriers of a BRCA1 mutation report a positive family history of breast or ovarian cancer (Figure 1). However, 45% of BRCA1 carriers report a negative family history, mainly because of paternal inheritance and incomplete penetrance (Figure 3) [20].


Hereditary breast and ovarian cancer.

Gronwald J, Byrski T, Huzarski T, Oszurek O, Janicka A, Szymanska-Pasternak J, Górski B, Menkiszak J, Rzepka-Górska I, Lubinski J - Hered Cancer Clin Pract (2008)

Family with HOC syndrome and diagnosed constitutional 4153delA BRCA1 gene mutation.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2735784&req=5

Figure 1: Family with HOC syndrome and diagnosed constitutional 4153delA BRCA1 gene mutation.
Mentions: Breast and ovarian cancer in BRCA1 carriers have particular clinical characteristics. The mean age at onset of breast cancer is about 42-45 years [15,16] and of ovarian cancer is about 54 years [17,18]. 18-32% of breast cancers are bilateral [19,20]. These are rapidly growing tumours: >90% of cases have G3 grade at the time of diagnosis and almost all ovarian cancers in women with a BRCA1 mutation are diagnosed in FIGO stage III°/IV°. Medullary, atypical medullary, ducal and oestrogen receptor negative (ER) breast tumours are common in BRCA1 carriers. BRCA1 mutation-positive tumours constitute about 10-15% of all ER-breast cancers [21-23]. Most carriers of a BRCA1 mutation report a positive family history of breast or ovarian cancer (Figure 1). However, 45% of BRCA1 carriers report a negative family history, mainly because of paternal inheritance and incomplete penetrance (Figure 3) [20].

View Article: PubMed Central - HTML - PubMed

Affiliation: International Hereditary Cancer Centre, Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland. jgron@sci.pam.szczecin.pl

ABSTRACT

Around 14 000 women develop breast or ovarian cancer in Poland every year. Advances in clinical genetics of cancers allow a significant number of these cancers to be prevented. Additionally, patients of known genetic background may be more effectively diagnosed and treated due to the application of special, nonstandard systems of control examinations and treatment.

No MeSH data available.